


U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Thallous Chloride TI 201. [Updated 2019 Jun 30]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Thallous Chloride Tl 201

Revised: June 30, 2019.

CASRN: 55172-29-7



Drug Levels and Effects

Summary of Use during Lactation

Information in this record refers to the use of thallous chloride Tl 201 as a diagnostic agent. Most experts recommend a period of breastfeeding interruption after maternal thallous chloride Tl 201, although some disagreement exists on the exact duration, probably because of the long physical half-life of the radioisotope and variable elimination of the drug from the body. One older paper recommends a 2-week discontinuation period after a dose of 110 MBq.[1] During the period of interruption, the breasts should be emptied regularly and completely. If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[2][3][4] The milk that is pumped by the mother during the time of breastfeeding interruption can either be discarded or stored frozen and given to the infant after 10 physical half-lives, or about 30 days, have elapsed. After doses greater than 150 MBq, consideration of temporarily limiting close contact between the mother and infant.[4]

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at background levels they may safely resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[5]

Dose	Duration of Interruption
100 MBq (3 mCi) 4 days[5][6]
80 MBq (2.4 mC	i) 10 hours[4]

Drug Levels

Thallium Tl 201 decays by electron capture with principal photon energies of 135.3 and 167.4 keV and a physical half-life of 3.044 days.[1] The effective half-life of thallous chloride Tl 201 ranges from 11 to 60.8 hours.[2]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Technetium Tc 99m Sestamibi, Technetium Tc 99m Tetrofosmin

References

- Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2. Available at: http:// www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/
- 2. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. Nucl Med Commun.1989;10:15-27. PubMed PMID: 2645546.
- 3. Early PJ, Sodee DB. Principles and practice of nuclear medicine. 2nd ed. St. Louis. Mosby-Year Book, Inc.1995:1380-1.
- 4. National Radiation Protection Board (UK). Administration of radioactive substances advisory committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2019. Available at: https://assets.publishing.service.gov.uk/government/.../file/.../ ARSAC_NfG_2019.pdf
- 5. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-73. PubMed PMID: 10809203.
- 6. International Atomic Energy Agency. Radiation Protection and Safety in Medical Uses of Ionizing Radiation, IAEA Safety Standards Series No. SSG-46, IAEA, Vienna. 2018. Available at: https://www.iaea.org/publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation

Substance Identification

Substance Name

Thallous Chloride Tl 201

CAS Registry Number

55172-29-7

Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Thallium Radioisotopes

Diagnostic Agents